BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Zenobia Therapeutics, Inc. Announces Sale of Commercial Fragment Library Ideal for Crystallographic, NMR and SPR Screening


3/2/2009 11:13:56 AM

LA JOLLA, Calif., March 2 /PRNewswire/ -- Zenobia Therapeutics, Inc. (Zenobia) the leader in fragment-based lead discovery (FBLD) for CNS diseases, announced today that they are adding a 352 compound fragment library to their product offerings. The library is ready for screening by X-ray, NMR, and SPR methods, contains soluble, verified protein binders, is shape and functionally diverse, and has an average molecular weight of 155 Da. The compounds are pre-plated and will initially cost ~ $11/compound. The library was constructed by Zenobia's team of seasoned FBLD professionals with over 25 years combined experience. Vicki Nienaber, Ph.D., President, CSO and founder of Zenobia, reported the first fragment-based crystallographic screening method in 2000.

"Over the past decade, FBLD has become a successful drug discovery method that has produced many NCEs and clinical candidates. We want FBLD to continue to positively impact drug discovery and are now providing a solid, simple starting point for fragment-based screening campaigns," said Dr. Nienaber. "A great deal of the chemical space of drug-like molecules can be covered by a well chosen set of small fragment compounds. This efficient library design will provide researchers with a lot of information on target site binding within a small number of experiments," said John Badger, Ph.D., Director of Structural Biology. The library has been examined by Dr. Ruo Steensma, Ph.D., Director of Chemistry for Zenobia Therapeutics. Dr. Steensma took forward two programs to IND using FBLD during her tenure as Director of Medicinal Chemistry at SGX Pharmaceuticals. "This is a perfect starting point for scientists interested in FBLD. The compounds are simple and ideally suited as starting points for further analoging. We look forward to working with fellow scientists who are interested in getting quality leads through this approach," said Dr. Steensma. Co-founder of Zenobia, Robert Meadows, Ph.D., a co-inventor of the SAR by NMR method who has designed multiple fragment libraries for the NMR screening method says, "Zenobia's library is a small, cherry picked selection of diverse chemotypes and shapes. And, since the compounds are all very soluble, screening with different methods is straightforward. Most importantly, once you find a hit with this library, developing the SAR is fast and economical." Through consulting or collaborations, Zenobia offers its expertise in advancing SAR around fragment hits.

About Zenobia

Zenobia provides a commercial fragment library, and access to their structural biology, crystallography and fragment-based lead discovery expertise through partnerships, consulting and collaborations. Zenobia's internal programs combine fragment-based lead discovery with the expertise of biologists and clinicians to find treatments for devastating illnesses for which there is no disease altering treatment such as Parkinson's and Huntington's disease.

For additional information on Zenobia Therapeutics, Inc., contact Dr. Vicki Nienaber at vicki@zenobiatherapeutics.com or visit www.zenobiatherapeutics.com. For additional information on Zenobia's fragment library, contact Dr. John Badger at john@zenobiatherapeutics.com.

CONTACT: Vicki Nienaber of Zenobia Therapeutics, +1-858-926-5780,
vicki@zenobiatherapeutics.com

Web site: http://www.zenobiatherapeutics.com/



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES